Zaltrap Approval History 
- FDA approved: Yes (First approved August 3rd, 2012)
- Brand name: Zaltrap
- Generic name: ziv-aflibercept
- Company: Sanofi and Regeneron Pharmaceuticals, Inc.
- Treatment for: Colorectal Cancer
Zaltrap (ziv-aflibercept) is an angiogenesis inhibitor for the combination treatment of patients with metastatic colorectal cancer.
FDA Approval History for Zaltrap
| Date | Article |
|---|---|
| Aug 3, 2012 |  FDA Approves Zaltrap for Metastatic Colorectal Cancer |
| Apr 5, 2012 | Sanofi and Regeneron Announce Regulatory and Clinical Update for Zaltrap (aflibercept) |
See also...
Zaltrap (ziv-aflibercept) Consumer Information
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
